C9077 — Injection, cabotegravir and rilpivirine, 2mg/3mg
C9077 is a HCPCS Level II code for injection, cabotegravir and rilpivirine, 2mg/3mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on September 30, 2021 and is not valid on new claims.
This code has been terminated
CMS terminated C9077 on September 30, 2021. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9077
- Long descriptor
- Injection, cabotegravir and rilpivirine, 2mg/3mg
- Short descriptor
- Inj cabotegravir/rilpivirine
- Added
- July 1, 2021
- Terminated
- September 30, 2021
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9077
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9077 is not quite right, the correct code is very often within a few positions of it.
- C9069Injection, belantamab mafodontin-blmf, 0.5 mgterminated
- C9070Injection, tafasitamab-cxix, 2 mgterminated
- C9071Injection, viltolarsen, 10 mgterminated
- C9072Injection, immune globulin (asceniv), 500 mgterminated
- C9073Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9074Injection, lumasiran, 0.5 mgterminated
- C9075Injection, casimersen, 10 mgterminated
- C9076Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9078Injection, trilaciclib, 1 mgterminated
- C9079Injection, evinacumab-dgnb, 5 mgterminated
- C9080Injection, melphalan flufenamide hydrochloride, 1 mgterminated
- C9081Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9082Injection, dostarlimab-gxly, 100 mgterminated
- C9083Injection, amivantamab-vmjw, 10 mgterminated
- C9084Injection, loncastuximab tesirine-lpyl, 0.1 mgterminated
- C9085Injection, avalglucosidase alfa-ngpt, 4 mgterminated
Questions about C9077
What is HCPCS code C9077?
C9077 is a HCPCS Level II code for injection, cabotegravir and rilpivirine, 2mg/3mg. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9077?
The CMS HCPCS file marks C9077 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9077 still valid?
No. C9077 was terminated on September 30, 2021 and should not be used on new claims.